{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T14:05:57Z","timestamp":1740146757767,"version":"3.37.3"},"reference-count":41,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T00:00:00Z","timestamp":1629072000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007212","name":"V\u00e4stra G\u00f6talandsregionen","doi-asserted-by":"publisher","award":["ALFGBG-717531"],"award-info":[{"award-number":["ALFGBG-717531"]}],"id":[{"id":"10.13039\/100007212","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007212","name":"V\u00e4stra G\u00f6talandsregionen","doi-asserted-by":"publisher","award":["ALFGBG-679621"],"award-info":[{"award-number":["ALFGBG-679621"]}],"id":[{"id":"10.13039\/100007212","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009252","name":"Science for Life Laboratory","doi-asserted-by":"publisher","award":["KAW 2020.0182"],"award-info":[{"award-number":["KAW 2020.0182"]}],"id":[{"id":"10.13039\/501100009252","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>Chloroquine was promoted as a COVID-19 therapeutic early in the pandemic. Most countries have since discontinued the use of chloroquine due to lack of evidence of any benefit and the risk of severe adverse events. The primary aim of this study was to examine if administering chloroquine during COVID-19 imposed an increased risk of ischemic heart injury or heart failure.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>Medical records, laboratory findings, and electrocardiograms of patients with COVID-19 who were treated with 500 mg chloroquine phosphate daily and controls not treated with chloroquine were reviewed retrospectively. Controls were matched in age and severity of disease.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>We included 20 patients receiving chloroquine (500 mg twice daily) for an average of five days, and 40 controls. The groups were comparable regarding demographics and biochemical analyses including C-reactive protein, thrombocytes, and creatinine. There were no statistically significant differences in cardiac biomarkers or in electrocardiograms. Median troponin T was 10,8 ng\/L in the study group and 17.9 ng\/L in the control group, whereas median NT-proBNP was 399 ng\/L in patients receiving chloroquine and 349 ng\/L in the controls.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>We found no increased risk of ischemic heart injury or heart failure as a result of administering chloroquine. However, the use of chloroquine to treat COVID-19 outside of clinical trials is not recommended, considering the lack of evidence of its effectiveness, as well as the elevated risk of fatal arrythmias.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0256035","type":"journal-article","created":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T18:35:29Z","timestamp":1629138929000},"page":"e0256035","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["No difference in biomarkers of ischemic heart injury and heart failure in patients with COVID-19 who received treatment with chloroquine phosphate and those who did not"],"prefix":"10.1371","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2400-4092","authenticated-orcid":true,"given":"Josefine","family":"Beck-Friis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susannah","family":"Leach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elmir","family":"Omerovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6422-604X","authenticated-orcid":true,"given":"Rickard","family":"Zeijlon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magnus","family":"Gisslen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aylin","family":"Yilmaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2021,8,16]]},"reference":[{"issue":"13","key":"pone.0256035.ref001","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1001\/jama.2020.2648","article-title":"Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention","volume":"323","author":"Z Wu","year":"2020","journal-title":"JAMA"},{"issue":"5","key":"pone.0256035.ref002","doi-asserted-by":"crossref","first-page":"362","DOI":"10.7326\/M20-3012","article-title":"Prevalence of Asymptomatic SARS-CoV-2 Infection: A Narrative Review","volume":"173","author":"DP Oran","year":"2020","journal-title":"Ann Intern Med"},{"issue":"11","key":"pone.0256035.ref003","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1001\/jama.2020.1585","article-title":"Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China","volume":"323","author":"D Wang","year":"2020","journal-title":"JAMA"},{"issue":"5","key":"pone.0256035.ref004","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/S2213-2600(20)30161-2","article-title":"Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations","volume":"8","author":"J Phua","year":"2020","journal-title":"Lancet Respir Med"},{"key":"pone.0256035.ref005","unstructured":"Intensivv\u00e5rdsregistret S. Svenska Intensivv\u00e5rdsregistret [cited 2020 December 1]. https:\/\/www.icuregswe.org\/data\u2014resultat\/covid-19-i-svensk-intensivvard\/."},{"key":"pone.0256035.ref006","unstructured":"EMA. Treatments and vaccines for COVID-19 [cited 2021 January 24]. https:\/\/www.ema.europa.eu\/en\/human-regulatory\/overview\/public-health-threats\/coronavirus-disease-covid-19\/treatments-vaccines-covid-19."},{"key":"#cr-split#-pone.0256035.ref007.1","unstructured":"FDA. Coronavirus disease 2019 (COVID-19), Resources for Health Professionals: FDA"},{"key":"#cr-split#-pone.0256035.ref007.2","unstructured":"[cited 2021 January 24]. https:\/\/www.fda.gov\/health-professionals\/coronavirus-disease-2019-covid-19-resources-health-professionals."},{"key":"pone.0256035.ref008","first-page":"1","article-title":"Old and re-purposed drugs for the treatment of COVID-19","author":"S-S Jean","year":"2020","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"2047\u20139980","key":"pone.0256035.ref009","article-title":"Chloroquine or Hydroxychloroquine for COVID-19: Is Cardiotoxicity a Concern?","author":"TJ Kamp","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"pone.0256035.ref010","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41584-020-0372-x","article-title":"Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology","volume":"16","author":"E Schrezenmeier","year":"2020","journal-title":"Nat Rev Rheumatol"},{"issue":"5","key":"pone.0256035.ref011","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s10787-015-0239-y","article-title":"Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases","volume":"23","author":"KD Rainsford","year":"2015","journal-title":"Inflammopharmacology"},{"issue":"7","key":"pone.0256035.ref012","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1093\/jac\/dkaa114","article-title":"COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression","volume":"75","author":"D Zhou","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"pone.0256035.ref013","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41421-020-0156-0","article-title":"Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro","volume":"6","author":"J Liu","year":"2020","journal-title":"Cell Discov"},{"issue":"1","key":"pone.0256035.ref014","doi-asserted-by":"crossref","first-page":"72","DOI":"10.5582\/bst.2020.01047","article-title":"Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies","volume":"14","author":"J Gao","year":"2020","journal-title":"Biosci Trends"},{"key":"pone.0256035.ref015","doi-asserted-by":"crossref","first-page":"101663","DOI":"10.1016\/j.tmaid.2020.101663","article-title":"Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study","author":"P Gautret","year":"2020","journal-title":"Travel Med Infect Dis"},{"key":"pone.0256035.ref016","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.ijcard.2020.05.036","article-title":"Arrhythmic profile and 24-hour QT interval variability in COVID-19 patients treated with Hydroxychloroquine and azithromycin","volume":"316","author":"A Cipriani","year":"2020","journal-title":"Int J Cardiol"},{"issue":"9","key":"pone.0256035.ref017","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1001\/jamacardio.2020.1834","article-title":"Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19)","volume":"5","author":"NJ Mercuro","year":"2020","journal-title":"JAMA Cardiol"},{"key":"pone.0256035.ref018","article-title":"Hydroxychloroquine for Early Treatment of Adults with Mild Covid-19: A Randomized-Controlled Trial","author":"O Mitja","year":"2020","journal-title":"Clin Infect Dis"},{"key":"pone.0256035.ref019","unstructured":"WHO. \u201cSolidarity\u201d clinical trial for COVID-19 treatments 2020 [https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019\/global-research-on-novel-coronavirus-2019-ncov\/solidarity-clinical-trial-for-covid-19-treatments."},{"issue":"21","key":"pone.0256035.ref020","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1001\/jama.2020.22240","article-title":"Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19: A Randomized Clinical Trial","volume":"324","author":"WH Self","year":"2020","journal-title":"JAMA"},{"issue":"4","key":"pone.0256035.ref021","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.medmal.2020.03.006","article-title":"No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection","volume":"50","author":"JM Molina","year":"2020","journal-title":"Med Mal Infect"},{"issue":"11","key":"pone.0256035.ref022","doi-asserted-by":"crossref","first-page":"754","DOI":"10.7326\/M20-1334","article-title":"Use of Hydroxychloroquine and Chloroquine During the COVID-19 Pandemic: What Every Clinician Should Know","volume":"172","author":"J Yazdany","year":"2020","journal-title":"Ann Intern Med"},{"key":"pone.0256035.ref023","unstructured":"CllinicalTrials.gov: U.S. National Library of Medicine; [cited 2021 18 June]. https:\/\/clinicaltrials.gov\/ct2\/results?cond=Covid19 HYPERLINK \"https:\/\/clinicaltrials.gov\/ct2\/results?cond=Covid19&term=chloroquine&cntry=&state=&city=&dist\"& HYPERLINK \"https:\/\/clinicaltrials.gov\/ct2\/results?cond=Covid19&term=chloroquine&cntry=&state=&city=&dist\"term=chloroquine HYPERLINK \"https:\/\/clinicaltrials.gov\/ct2\/results?cond=Covid19&term=chloroquine&cntry=&state=&city=&dist\"& HYPERLINK \"https:\/\/clinicaltrials.gov\/ct2\/results?cond=Covid19&term=chloroquine&cntry=&state=&city=&dist\"cntry = HYPERLINK \"https:\/\/clinicaltrials.gov\/ct2\/results?cond=Covid19&term=chloroquine&cntry=&state=&city=&dist\"& HYPERLINK \"https:\/\/clinicaltrials.gov\/ct2\/results?cond=Covid19&term=chloroquine&cntry=&state=&city=&dist\"state = HYPERLINK \"https:\/\/clinicaltrials.gov\/ct2\/results?cond=Covid19&term=chloroquine&cntry=&state=&city=&dist\"& HYPERLINK \"https:\/\/clinicaltrials.gov\/ct2\/results?cond=Covid19&term=chloroquine&cntry=&state=&city=&dist\"city = HYPERLINK \"https:\/\/clinicaltrials.gov\/ct2\/results?cond=Covid19&term=chloroquine&cntry=&state=&city=&dist\"& HYPERLINK \"https:\/\/clinicaltrials.gov\/ct2\/results?cond=Covid19&term=chloroquine&cntry=&state=&city=&dist\"dist =."},{"key":"pone.0256035.ref024","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1743-422X-2-69","article-title":"Chloroquine is a potent inhibitor of SARS coronavirus infection and spread","volume":"2","author":"MJ Vincent","year":"2005","journal-title":"Virol J"},{"issue":"9","key":"pone.0256035.ref025","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/S1473-3099(11)70065-2","article-title":"Chloroquine for influenza prevention: a randomised, double-blind, placebo controlled trial","volume":"11","author":"NI Paton","year":"2011","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"pone.0256035.ref026","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0035-9203(87)90298-7","article-title":"Aedes aegypti and yellow fever virus: the effect of chloroquine on infection and transmission rates","volume":"81","author":"BR Miller","year":"1987","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"4","key":"pone.0256035.ref027","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/0149-2918(95)80039-5","article-title":"Hydroxychloroquine treatment of patients with human immunodeficiency virus type 1","volume":"17","author":"K Sperber","year":"1995","journal-title":"Clin Ther"},{"issue":"10","key":"pone.0256035.ref028","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s40264-018-0689-4","article-title":"Cardiac Complications Attributed to Chloroquine and Hydroxychloroquine: A Systematic Review of the Literature","volume":"41","author":"C Chatre","year":"2018","journal-title":"Drug Saf"},{"issue":"1533\u20134406","key":"pone.0256035.ref029","article-title":"Risk of myocardial infarction and stroke after acute infection or vaccination","author":"L Smeeth","journal-title":"N Engl J Med"},{"issue":"1524\u20134539","key":"pone.0256035.ref030","article-title":"Cardiac complications in patients with community-acquired pneumonia: incidence, timing, risk factors, and association with short-term mortality","author":"VF Corrales-Medina","journal-title":"Circulation"},{"issue":"10229","key":"pone.0256035.ref031","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study","volume":"395","author":"F Zhou","year":"2020","journal-title":"Lancet (London, England)"},{"issue":"2","key":"pone.0256035.ref032","doi-asserted-by":"crossref","first-page":"e0247800","DOI":"10.1371\/journal.pone.0247800","article-title":"Myocardial injury in hospitalized patients with COVID-19 infection-Risk factors and outcomes","volume":"16","author":"O Efros","year":"2021","journal-title":"PLoS One"},{"issue":"19","key":"pone.0256035.ref033","doi-asserted-by":"crossref","first-page":"e008032","DOI":"10.1161\/JAHA.117.008032","article-title":"Cardiac Troponins for the Diagnosis of Acute Myocardial Infarction in Chronic Kidney Disease","volume":"7","author":"D Kraus","year":"2018","journal-title":"J Am Heart Assoc"},{"issue":"4","key":"pone.0256035.ref034","doi-asserted-by":"crossref","first-page":"678","DOI":"10.21037\/cdt-20-510","article-title":"Analysis of influencing factors related to elevated serum troponin I level for COVID-19 patients in Yichang, China","volume":"10","author":"ZX Fan","year":"2020","journal-title":"Cardiovasc Diagn Ther"},{"issue":"10","key":"pone.0256035.ref035","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10102096","article-title":"Myocardial Injury in COVID-19 Patients: Association with Inflammation, Coagulopathy and In-Hospital Prognosis","volume":"10","author":"V Arevalos","year":"2021","journal-title":"J Clin Med"},{"issue":"10","key":"pone.0256035.ref036","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9103263","article-title":"Redefining the Prognostic Value of High-Sensitivity Troponin in COVID-19 Patients: The Importance of Concomitant Coronary Artery Disease","volume":"9","author":"M Schiavone","year":"2020","journal-title":"J Clin Med"},{"issue":"1540\u20138167","key":"pone.0256035.ref037","article-title":"Incidence and Determinants of QT Interval Prolongation in COVID-19 Patients Treated with Hydroxychloroquine and Azithromycin","author":"I Maraj","journal-title":"J Cardiovasc Electrophysiol"},{"issue":"7\u20138","key":"pone.0256035.ref038","first-page":"418","article-title":"The risk of QTc-interval prolongation in COVID-19 patients treated with chloroquine","volume":"28","author":"FS Sinkeler","journal-title":"Neth Heart J"},{"issue":"12","key":"pone.0256035.ref039","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1093\/europace\/euaa216","article-title":"Arrhythmic safety of hydroxychloroquine in COVID-19 patients from different clinical settings","volume":"22","author":"A Gasperetti","year":"2020","journal-title":"Europace"},{"issue":"1","key":"pone.0256035.ref040","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jacep.2020.07.016","article-title":"Hydroxychloroquine\/Azithromycin Therapy and QT Prolongation in Hospitalized Patients With COVID-19","volume":"7","author":"TF O\u2019Connell","year":"2021","journal-title":"JACC Clin Electrophysiol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0256035","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T18:36:44Z","timestamp":1629139004000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0256035"}},"subtitle":[],"editor":[{"given":"C\u00e9cile","family":"Oury","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2021,8,16]]},"references-count":41,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2021,8,16]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0256035","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2021,8,16]]}}}